Rock Point Advisors LLC Buys 29,658 Shares of Pfizer Inc. $PFE

Rock Point Advisors LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 31.5% during the third quarter, HoldingsChannel.com reports. The fund owned 123,667 shares of the biopharmaceutical company’s stock after purchasing an additional 29,658 shares during the quarter. Rock Point Advisors LLC’s holdings in Pfizer were worth $3,151,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of PFE. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer in the third quarter worth about $29,000. Howard Hughes Medical Institute bought a new stake in Pfizer in the 2nd quarter worth approximately $30,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $32,000. Evelyn Partners Asset Management Ltd purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $33,000. Finally, True Wealth Design LLC boosted its position in shares of Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PFE. Bank of America reduced their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Scotiabank initiated coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Barclays began coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, UBS Group assumed coverage on Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.05.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: PF-07328948 kidney-function Phase 1 progress — Pfizer updated an ongoing study that management says supports long‑term pipeline value, reinforcing future R&D upside. Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
• Positive Sentiment: Oncology milestones broaden non‑COVID revenue path — Phase 3 PADCEV + Keytruda data and a full FDA approval for a BRAFTOVI regimen are material near‑term clinical wins that boost recurring oncology revenue prospects. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
• Positive Sentiment: Dividend/defensive narrative supports demand — MarketBeat highlights Pfizer’s 6%+ yield and defensive appeal amid volatility, which can attract income‑seeking flows into PFE. The Dividend Safe Harbor: 2 Stocks to Watch
• Positive Sentiment: Analyst upgrade — Argus raised Pfizer to Buy with a $35 target, signaling upside from current levels and likely supporting positioning by discretionary investors. Benzinga coverage of Argus upgrade
• Neutral Sentiment: AI adoption in manufacturing — A market report cites Pfizer among majors integrating AI (predictive maintenance, quality control). It’s a positive long‑term efficiency story but not an immediate revenue catalyst. AI in Pharma Manufacturing Market Research 2026-2040
• Neutral Sentiment: “Quiet cash comeback” narrative — Commentary on improving cash generation supports the valuation case, but it’s an incremental theme rather than a single price mover. Pfizer’s Quiet Cash Comeback
• Negative Sentiment: Zumrad EMA filing withdrawn — Pfizer pulled its Zumrad application in Europe, a clear regulatory setback that removes a near‑term approval pathway and can pressure sentiment. Pfizer withdraws Zumrad EMA filing
• Negative Sentiment: CEO flags issues with FDA vaccine leadership — Public criticism of the FDA’s vaccine leadership introduces regulatory uncertainty and could complicate future review processes or timelines. Pfizer CEO flags issues with FDA’s vaccine leadership

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.60 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The stock’s fifty day moving average is $26.20 and its two-hundred day moving average is $25.44. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The company has a market capitalization of $151.25 billion, a PE ratio of 19.56 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.63 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.